

Press release

Lund, 15th January, 2026
EQL Pharma AB (publ)
556713-3425

EQL PHARMA

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3rd.

At 10.00 (CET) 4th February, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate.

Use the following link to access the virtual meeting: <https://tinyurl.com/mpmbyxxn>

Date and time

February 4th, 2026, at 10.00 (CET) the presentation starts. Time required for presentation and subsequent question time is estimated at a maximum 1 hour.

Make sure you are able to attend the video conference by logging in shortly before the start of the conference.

For further information, please contact:

Axel Schörling

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.